Receive The Newest Study Notifications

Soliton Announces Majority of Patients Treated in Pivotal Cellulite Trial; Expects All Patients Treated by November 2019

by Lance Smith | Sep 24, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Soliton, Inc., (SOLY) (“Soliton” or the “Company”), a medical device company with a novel and proprietary platform technology licensed from The University of Texas on behalf of the MD Anderson Cancer Center (“MD Anderson”), today...

Personalized Stem Cells, Inc. Announces Clinical Trial Sites Qualified for FDA Approved Clinical Trial for Treatment of Osteoarthritis with Stem Cells

by Lance Smith | Sep 24, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Personalized Stem Cells, Inc. announces clinical trial sites qualified for FDA approved clinical trial for treatment of osteoarthritis with stem cells. Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, has completed training and site...

Abeona Therapeutics Provides Regulatory Update Ahead of Pivotal Phase 3 Clinical Trial for EB-101 in Recessive Dystrophic Epidermolysis Bullosa

by Lance Smith | Sep 24, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Company to provide additional transport stability data points in response to FDA Clinical Hold Letter CMC clearance for VIITAL™ trial anticipated in Q4 2019 Investor conference call today, Monday, September 23 at 09:30 a.m. ET NEW YORK and CLEVELAND, Sept. 23, 2019...

Cardax Announces Interim Results from CHASE Clinical Trial

by Lance Smith | Sep 24, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Pre-Specified Interim Review Demonstrated Beneficial Changes in Markers of Cardiovascular Health – CRP, LDL, total cholesterol, triglycerides, oxidized LDL, and blood pressure reduced – Interim results support excellent safety profile – Enrollment...

Rigel’s fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia

by Lance Smith | Sep 24, 2019 | Study Scavenger Clinical Trial Recruitment Platform

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its collaboration partner, Kissei Pharmaceuticals Co., Ltd. (“Kissei”), has initiated a Phase 3 trial in Japan of fostamatinib disodium hexahydrate in adult patients with chronic immune...

Mallinckrodt Announces Positive Top-line Results from Pivotal Phase 3 Clinical Trial of StrataGraft® Regenerative Tissue in Patients with Deep Partial-thickness Thermal Burns

by Lance Smith | Sep 24, 2019 | Study Scavenger Clinical Trial Recruitment Platform

– Study met both co-primary endpoints with high statistical significance, demonstrating autograft sparing and durable wound closure at three months with StrataGraft – – Company plans to submit Biologics License Application to the U.S. Food and Drug...